RESUMEN
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is caused by thymidine phosphorylase (TP) deficiency, which leads to toxic accumulations of thymidine (dThd) and deoxyuridine (dUrd). In this work, we report that infusion of platelets from healthy donors to patients with MNGIE restored transiently circulating TP and reduced plasma dThd and dUrd levels, suggesting that treatments to achieve permanent restoration of circulating TP such as allogeneic stem cell transplantation or gene transfer might be therapeutic.
Asunto(s)
Desoxiuridina/antagonistas & inhibidores , Enfermedades Gastrointestinales/terapia , Encefalomiopatías Mitocondriales/terapia , Enfermedades del Sistema Nervioso/terapia , Transfusión de Plaquetas , Timidina Fosforilasa/sangre , Timidina/antagonistas & inhibidores , Adolescente , Adulto , Desoxiuridina/sangre , Femenino , Enfermedades Gastrointestinales/sangre , Humanos , Masculino , Encefalomiopatías Mitocondriales/sangre , Enfermedades del Sistema Nervioso/sangre , Timidina/sangreRESUMEN
Neutrophil hypersegmentation is considered the most sensitive peripheral blood cell marker of cobalamin deficiency. However, its diagnostic value in the mild deficiency states that accompany most low cobalamin levels and its relation to metabolic test of cobalamin status are unknown. The authors compared neutrophil lobe averages and percent neutrophils with 5 or more lobes (%5+ lobes) in 169 subjects with their mean corpuscular volume (MCV) and serum cobalamin, methylmalonic acid (MMA), homocysteine, and folate levels and, in 65 cases, with the deoxyuridine suppression test (dUST). Only 9 subjects had hypersegmentation by lobe average and 20 subjects by %5+ lobes. They were not more often cobalamin-deficient than subjects without hypersegmentation. Moreover, only one of 34 subjects with dUST results diagnostic for cobalamin deficiency had neutrophil hypersegmentation. Both indices of neutrophil segmentation in the 169 subjects correlated significantly with homocysteine levels. They also showed weak inverse correlation with cobalamin levels, but did not correlate with MMA, folate, or MCV values. Cobalamin therapy for 6 months did not significantly change neutrophil lobe averages in 35 subjects with mild deficiency, compared with 8 nondeficient controls, and only marginally improved the %5+ lobes. A surprising, incidental observation was that blacks had significantly greater neutrophil segmentation by both criteria than did whites and others. This difference was unrelated to cobalamin or folate status. Our results indicate that dUST abnormalities precede all morphologic changes of deficiency, including hypersegmentation. Although a tendency exists for neutrophil segmentation to increase very slightly as some serum values, especially homocysteine, start to worsen in mild cobalamin deficiency, the metabolic changes precede overt hypersegmentation. Neutrophil nuclear segmentation is insufficiently sensitive in relation to metabolic evidence of deficiency to be used as a clinical tool in the diagnosis of mild cobalamin deficiency.
Asunto(s)
Núcleo Celular/patología , Neutrófilos/patología , Deficiencia de Vitamina B 12/sangre , Deficiencia de Vitamina B 12/etnología , Vitamina B 12/metabolismo , Pueblo Asiatico , Población Negra , Médula Ósea/metabolismo , Desoxiuridina/antagonistas & inhibidores , Femenino , Hispánicos o Latinos , Humanos , Los Angeles/etnología , Masculino , Vitamina B 12/uso terapéutico , Deficiencia de Vitamina B 12/tratamiento farmacológico , Población BlancaRESUMEN
Long-term therapy of AIDS patients with 3'-azido-3'-deoxythymidine (AZT) remains of concern because of resulting hematopoietic toxicity. While the mechanism(s) of this toxicity remains elusive, alternative strategies are being developed to reduce these toxic effects, including combination therapy with nonmyelotoxic antihuman immunodeficiency virus drugs and/or administration of protective or rescue agents, including cytokines and growth factors. By using a particularly relevant human CD34+ liquid culture system, the unique profiles of dideoxynucleoside (ddN) toxicities to both proliferation and differentiation were demonstrated, with decreased potencies in the order of 3'-fluoro-3'-deoxythymidine (FLT) = 3'-amino-3'-deoxythymidine (AMT) = 2',3'-dideoxycytidine > AZT for inhibition of proliferation and in the order of FLT = AMT > AZT >> 2',3'-dideoxycytidine for inhibition of hemoglobin synthesis. Hemin selectively protected erythroid-lineage human burst-forming unit-erythroid cells from AZT- and AMT-induced inhibition but had no effect on FLT toxicity under similar conditions. Myeloid-lineage human CFU-granulocyte-macrophages were also not protected by hemin against all three ddN analogs. The simultaneous exposure of cells to hemin and AZT resulted in a complete protection of both cell proliferation and hemoglobin synthesis. In contrast, in reversal studies only the inhibition of the percentage of hemoglobin-synthesizing cells returned to control levels, but the inhibition of proliferation of cells previously exposed to AZT was not reversed by hemin. These studies further define the unique and multifactorial mechanism(s) of ddN-induced toxic effects during hematopoietic development of pluripotent stem cells and suggest that the use of hemin could be beneficial in alleviating the toxicity of certain ddN analogs.
Asunto(s)
Células de la Médula Ósea , Médula Ósea/efectos de los fármacos , Desoxiuridina/análogos & derivados , Desoxiuridina/toxicidad , Células Madre Hematopoyéticas/efectos de los fármacos , Hemina/farmacología , Antígenos CD34/análisis , Diferenciación Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Ensayo de Unidades Formadoras de Colonias , Desoxiuridina/antagonistas & inhibidores , Células Precursoras Eritroides/clasificación , Células Precursoras Eritroides/efectos de los fármacos , Humanos , Zidovudina/antagonistas & inhibidores , Zidovudina/toxicidadRESUMEN
In a chronic toxicity study in the rat, bidisomide administered as a dietary admixture produced a dose-related lowering of reticulocytes and leucocytes. Plasma alanine aminotransferase activity was increased at 300 mg/kg and decreased at 900 mg/kg. The potential mechanisms of these effects were investigated by comparing the responses in groups of male Sprague-Dawley rats receiving a control diet, or 300 or 1200 mg/kg/day bidisomide. Subsets of these groups were co-treated subcutaneously with folinic acid or with a vitamin B1, B6, B12 complex. Subsets of control and 300 mg/kg groups were maintained on a 20-25% feed restriction regimen for 3 months, to mimic the depression in body weight gain observed in animals receiving 1200 mg/kg. Body weight gains were significantly reduced at 1200 mg/kg and in all feed-restricted animals. Plasma and liver alanine aminotransferase (ALT) and plasma aspartate aminotransferase (AST) levels were also reduced at this dose level. At 300 mg/kg, plasma transaminases, glutamate dehydrogenase (GLDH) and sorbitol dehydrogenase (SDH) activities were increased. These changes were prevented in animals receiving folinic acid supplementation. Plasma glucose, triglycerides, and unsaturated and total iron binding capacities were decreased, while plasma iron levels tended to increase, mainly at the high dose. Vitamin supplementation prevented a decrease in reticulocyte counts at 300 mg/kg. Bidisomide increased urinary formimino-glutamic acid (FIGLU) excretion but did not affect methylmalonic acid (MMA) or taurine excretion. The effect on FIGLU at 1200 mg/kg was prevented by folinic acid co-treatment. Absolute liver weight was lowered at both dose levels and in feed-restricted animals. However, the relative liver weights were unaffected. Thymidine kinase and thymidylate synthase activity of the bone marrow cells were not altered by the bidisomide treatment. Except for the increase in plasma transaminase, GLDH and SDH levels at 300 mg/kg, changes in clinical chemistry parameters are considered to result mainly from nutritional restrictions. Changes in hematologic parameters appear to be related to the combination of decreased feed consumption (leukocytes) and decreased availability or utilization of folates (reticulocytes). This alteration, however, did not affect DNA synthesis in bone marrow. The prevention by folinic acid, but not by feed restriction, of the elevation of liver enzymes at 300 mg/kg is an intriguing, yet unexplained finding. There was no evidence that bidisomide affected B6 and B12 availability.
Asunto(s)
Antiarrítmicos/toxicidad , Antídotos/farmacología , Leucovorina/administración & dosificación , Piperidinas/toxicidad , Complejo Vitamínico B/administración & dosificación , Alanina Transaminasa/sangre , Análisis de Varianza , Animales , Antiarrítmicos/administración & dosificación , Antídotos/administración & dosificación , Aspartato Aminotransferasas/sangre , Peso Corporal/efectos de los fármacos , Médula Ósea/efectos de los fármacos , Células de la Médula Ósea , ADN/metabolismo , Desoxiuridina/antagonistas & inhibidores , Dieta , Ingestión de Alimentos/efectos de los fármacos , Fémur/citología , Fémur/efectos de los fármacos , Privación de Alimentos , Ácido Formiminoglutámico/orina , Cromatografía de Gases y Espectrometría de Masas , Técnicas In Vitro , Leucovorina/farmacología , Masculino , Ácido Metilmalónico/orina , Piperidinas/administración & dosificación , Ratas , Ratas Sprague-Dawley , Taurina/orina , Complejo Vitamínico B/farmacología , Aumento de Peso/efectos de los fármacosRESUMEN
N2O is a relatively safe general anaesthetic under normal medical and dental anaesthetic use. It is more likely to produce megaloblastosis or neuropathy when used repetitively or for periods longer than 3 hours or in individuals with vitamin B12 deficiencies. The mechanism responsible for its myelotoxicity, neurotoxicity and most likely its reproductive toxicity, involves its inhibition of MetSyn and the resulting reduction in SAM and THF levels. Administration of folinic acid or methionine have been shown to protect against megaloblastosis and neurotoxicity occurring following N2O administration. Occupational N2O exposure of medical and dental personnel during its use as an analgesic is not likely to produce adverse reproductive outcomes except in B12-deficient individuals or in those routinely exposed to high N2O levels.
Asunto(s)
Médula Ósea/efectos de los fármacos , Neurotoxinas/efectos adversos , Óxido Nitroso/efectos adversos , Reproducción/efectos de los fármacos , 5-Metiltetrahidrofolato-Homocisteína S-Metiltransferasa/antagonistas & inhibidores , Anemia Perniciosa/inducido químicamente , Animales , Médula Ósea/enzimología , Médula Ósea/metabolismo , ADN/biosíntesis , Desoxiuridina/antagonistas & inhibidores , Femenino , Humanos , Neurotoxinas/toxicidad , Óxido Nitroso/administración & dosificación , Óxido Nitroso/toxicidad , Embarazo , Purinas/biosíntesis , Deficiencia de Vitamina B 12/inducido químicamente , Deficiencia de Vitamina B 12/complicaciones , Deficiencia de Vitamina B 12/metabolismoRESUMEN
The effects of crude bone morphogenetic protein (BMP) derived from bone and dentin matrix on proliferation, production of extracellular matrix, and biologic function of the pulp cell were examined in the primary cell culture from permanent dental pulp. BMP from bone and from dentin matrix stimulated iodine 125-deoxyuridine incorporation in the absence of 10% calf serum. They increased sulfur 35-sulfate incorporation in proliferating stage and had no effects in stationary stage of culture. Alkaline phosphatase activities were inhibited in proliferating, stationary, and multilayered stages of culture. Osteocalcin synthesis was increased in culture treated with BMP from day 2 to day 10. These findings suggest that crude BMP might have mitogenic activity and some role in regulation of differentiation of pulp cells into odontoblasts.
Asunto(s)
Pulpa Dental/efectos de los fármacos , Dentinogénesis/efectos de los fármacos , Sustancias de Crecimiento/farmacología , Mitógenos/farmacología , Proteínas/farmacología , Fosfatasa Alcalina/antagonistas & inhibidores , Fosfatasa Alcalina/metabolismo , Animales , Biomarcadores , Proteínas Morfogenéticas Óseas , Huesos/química , Bovinos , División Celular , Células Cultivadas , Medios de Cultivo , Pulpa Dental/citología , Pulpa Dental/enzimología , Pulpa Dental/metabolismo , Dentina/química , Desoxiuridina/antagonistas & inhibidores , Desoxiuridina/metabolismo , Perros , Sustancias de Crecimiento/análisis , Osteocalcina/biosíntesis , Proteínas/análisis , Proteoglicanos/biosíntesis , Sulfatos/antagonistas & inhibidores , Sulfatos/metabolismoRESUMEN
The type III transforming growth factor-beta (TGF-beta) receptor is a cell surface chondroitin/heparan sulfate proteoglycan that binds various forms of TGF-beta with high affinity and specificity. Here, we have used a genetic approach to determine the requirement for glycosaminoglycan (GAG) chains for normal TGF-beta receptor expression and the role that the receptor proteoglycan core and GAG chains play in TGF-beta binding. Chinese hamster ovary (CHO) cells defective in GAG synthesis express on their surface 110-130-kDa type III receptor proteoglycan cores that can bind normal levels of TGF-beta compared to wild type CHO cells. The affinity of the receptor core for TGF-beta 1 and TGF-beta 2 in CHO cell mutants is similar to that of the TGF-beta receptor proteoglycan forms present in wild type CHO cells or in CHO cell mutants that have been allowed to bypass their metabolic defect and express the wild type proteoglycan phenotype. The binding properties of TGF-beta receptor types I and II in CHO cells and the growth-inhibitory response of CHO cell mutants to TGF-beta are not impaired by the absence of GAG chains in the type III receptor. These results show that the GAG chains are dispensable for type III receptor expression on the cell surface, binding of TGF-beta to the receptor core, and growth inhibitory response of the cells to TGF-beta. The evidence also suggests that the type III receptor may act as a multifunctional proteoglycan able to bind TGF-beta via the receptor core while performing another as yet unidentified function(s) via the GAG chains.
Asunto(s)
Glicosaminoglicanos , Proteoglicanos/metabolismo , Receptores de Superficie Celular/metabolismo , Factores de Crecimiento Transformadores/metabolismo , Acetilgalactosamina/farmacología , Animales , Línea Celular , Cricetinae , Cricetulus , Desoxiuridina/antagonistas & inhibidores , Electroforesis en Gel de Poliacrilamida , Galactosa/farmacología , Mutación , Receptores de Superficie Celular/efectos de los fármacos , Receptores de Superficie Celular/genética , Receptores de Factores de Crecimiento Transformadores betaRESUMEN
The effects of 24 hours of nitrous oxide exposure on reproductive indices and fetal development were examined in Sprague-Dawley rats. Four different experiments employing four concentrations of nitrous oxide--0.75%, 7.5%, 25% and 75%--established that the threshold of toxicity was greater than 25%. At 75% nitrous oxide there was a significant increase in early and late resorptions, and a consistent teratogenic effect (e.g., runts, ocular malformations, limb deformities). Neither the stress of shipping dams while pregnant nor the withholding of food during nitrous oxide exposure resulted in additional adverse effects. Exposure to 25% nitrous oxide was associated with increased deoxyuridine suppression values; however, adverse reproductive effects were not seen at this nitrous oxide concentration. The results of this and other studies which have examined the reproductive and teratogenic effects of nitrous oxide do not contraindicate its use in operating rooms nor, when necessary, as an anesthetic for pregnant surgical patients.
Asunto(s)
Desarrollo Embrionario y Fetal/efectos de los fármacos , Óxido Nitroso/farmacología , Efectos Tardíos de la Exposición Prenatal , Ratas/fisiología , Reproducción/efectos de los fármacos , Anomalías Inducidas por Medicamentos/patología , Animales , Conducta Animal/efectos de los fármacos , Desoxiuridina/antagonistas & inhibidores , Relación Dosis-Respuesta a Droga , Femenino , Óxido Nitroso/efectos adversos , Embarazo , Ratas EndogámicasAsunto(s)
Fluorouracilo/administración & dosificación , Adenocarcinoma/sangre , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/metabolismo , Administración Oral , Disponibilidad Biológica , Médula Ósea/análisis , Médula Ósea/efectos de los fármacos , Médula Ósea/metabolismo , Células de la Médula Ósea , Radioisótopos de Carbono , Ensayos Clínicos como Asunto , Desoxiuridina/antagonistas & inhibidores , Desoxiuridina/metabolismo , Fluorouracilo/análisis , Fluorouracilo/sangre , Fluorouracilo/metabolismo , Fluorouracilo/farmacología , Fluorouracilo/uso terapéutico , Semivida , Humanos , Inyecciones Intravenosas , Cinética , Vehículos Farmacéuticos , Timidina/antagonistas & inhibidores , Timidina/metabolismo , Factores de TiempoAsunto(s)
Anemia Macrocítica/metabolismo , Células de la Médula Ósea , Médula Ósea/metabolismo , Ácido Fólico/metabolismo , Glutamatos/metabolismo , Linfocitos/metabolismo , Transporte Biológico , Coenzimas/fisiología , ADN/biosíntesis , Desoxiuridina/antagonistas & inhibidores , Desoxiuridina/farmacología , Humanos , Pirimidinas/metabolismo , Relación Estructura-Actividad , Timidina/metabolismo , TritioRESUMEN
Cordycepin (3'-deoxyadenosine), an inhibitor of poly(A) synthesis during the processing of nuclear heterogenous RNA, blocks the production of RNA viruses induced by 5-iodo-2'-deoxyuridine in BALB/3T3 and BALB/K-3T3 cells. This inhibitory activity is not a result of either nonspecific cell killing or general cytotoxicity by cordycepin; rather, it appears to be specific, because cordycepin acts only at a critical time to inhibit virus production. These findings, together with the finding of poly(A) sequences in viral RNAs, suggest that RNA tumor viruses replicate via a transcription of proviral DNA.